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Abstract
Background
The clinical syndrome cancer cachexia is recognized by a considerable weight loss be-
ing out of proportion to any reduction in energy intake. The underlying mechanisms 
are not completely known, but the marked weight loss is attributable to depletion of 
adipose tissue as well as skeletal muscle mass. Enhanced lipolysis in adipocytes, apop-
tosis of preadipocytes may be important for loss of adipose tissue. 
Results
Sera from cachectic cancer patients induced apoptosis in cultured human preadipo-
cytes at a higher rate than sera from non-cachectic cancer patients (control group). 
There was a tendency towards increased mRNA levels of the pro-apoptotic Bcl-2 gene 
Bax after incubation of preadipocytes with cachectic sera. Moreover, the mRNA lev-
els of anti-apoptotic Bcl-XL and pro-apoptotic Bcl-XS were increased and decreased, 
respectively, as compared to incubation with control sera. However, lipolysis was not 
enhanced in cultured human adipocytes after incubation with sera from cachectic 
cancer patients as compared to non-cachectic cancer patients. 
Methods
Serum samples from cachectic cancer patients (n=8) and non-cachectic cancer pa-
tients (n=6) were collected. Human SGBS (Simpson-Golabi-Behmel syndrome) pre-
adipocytes and differentiated adipocytes were incubated in the presence of serum 
from cachectic and non-cachectic (control) cancer patients. Induction of apoptosis 
and necrosis was examined by cell staining with Hoechst 342 (HO342) and propidium 
iodide (PI), respectively. Expression of pro- and anti-apoptotic Bcl-2 genes was mea-
sured by quantitative RT-PCR. Lipolysis was monitored by measuring the release of 
radiolabeled fatty acids.
Conclusion
Our in vitro data suggest that apoptosis of preadipocytes can be increased by serum-
borne factors in cancer cachexia. Death or survival of preadipocytes may depend on 
the balance of pro- and anti-apoptotic mediators. Further studies of patients with can-
cer cachexia will be needed to reveal if the disease involves loss of adipose tissue due 
to apoptosis of preadipocytes. We could not show that serum-borne factors associ-
ated with cachexia have a major impact on lipolysis in cultured human adipocytes.
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Introduction
Ca��ex�a �s ��ara�ter�zed �y marked 
�e���t loss �� ��d�v�d�als ��t� sys�
tem�� �o�d�t�o�s l�ke �a��ers or ser��
o�s ��fe�t�o�s. The �e���t loss �s re�
fle�ted as a red��t�o� �� �ot� ad�pose 
t�ss�e a�d skeletal m�s�le mass, a�d 
�t �a��ot �e expla��ed �y a�orex�a 
alo�e �e�a�se �t �s �ot reversed �y 
s�ppleme�tat�o� of ��tr�e�ts (1). Th�s 
s���ests t�at a s����fi�a�t meta�ol�� 
�ompo�e�t �s ��volved (2). Approx��
mately 50 % of late sta�e d�seased �a��
�er pat�e�ts develop �a��ex�a a�d t�e 
o���rre��e �s espe��ally ���� amo�� 
pat�e�ts ��t� pa��reat�� a�d �astr�� 
�a��ers, ��ere a�o�t 83�87 % s�ffers 
from �a��ex�a (3). 
 Ad�pose t�ss�e ���l�des a �etero�e�
�eo�s pop�lat�o� of �ells l�ke mat�re 
���te ad�po�ytes, T��ells, de�dr�t�� 
�ells, �erve �ells a�d e�dot�el�al �ells 
(4). A stem �ell pop�lat�o� ��t��� t�e 
ad�pose stromal �ompartme�t �a� 
�e d�ffere�t�ated in vitro to�ard t�e 
ad�po�e��� as �ell as ot�er l��ea�es 
(5). Ad�pose t�ss�es �a� also �omm��
���ate ��t� ot�er t�ss�es �� t�e �ody 
�y prod��t�o� a�d release of several 
�ormo�es, termed ad�pok��es, t�at 
may a�t lo�ally or system��ally to alter 
ma�y ��olo���al pro�esses l�ke e�er�y 
expe�d�t�re a�d food ��take (6). D�r�
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��� starvat�o�, t�e �asal meta�ol�� rate �s red��ed as t�e �ody 
adapts to �o�serve e�er�y as �ell as m�s�le a�d ad�pose t�ss�es 
(7). �� �o�trast, �a��er �a��ex�a �s assos�ated ��t� e��a��ed or 
����a��ed e�er�y expe�d�t�re a�d loss of �ot� ad�pose a�d 
m�s�le t�ss�e (8�11). T�o pro�esses may determ��e ad�pose t�s�
s�e mass �� �a��ex�a: red��ed ad�po�yte s�ze (�ypotrop�y) a�d 
de�reased ad�po�yte ��m�er (�ypoplas�a). 
 The �ydrolys�s of tr��ly�er�des from ad�pose t�ss�e �a� �e re��
�lated �y a �AMP�med�ated pro�ess ��volv��� �ot� �ormo�e�
se�s�t�ve l�pase (�SL) a�d l�p�d droplet s�rfa�e prote��s l�ke 
per�l�p�� (12). �ypotrop�y of ad�po�ytes seems to ar�se from a� 
���rease �� l�polys�s, rat�er t�a� a de�rease �� l�po�e�es�s (13). 
 The ��m�er of ad�po�ytes prese�t �� a� or�a��sm may �e 
��fl�e��ed �y t�e ad�po�yte d�ffere�t�at�o� pro�ess, ����� �e��
erates mat�re ad�po�ytes from pro�e��tor �ells, ro���ly termed 
pread�po�ytes. Deplet�o� of t�ese pro�e��tor �ells, o���rr��� �y 
apoptos�s or �e�ros�s, may l�m�t t�e re�e�erat�o� of ad�po�ytes 
a�d res�lt �� loss of ad�pose t�ss�e. The B�l�2 fam�ly �s a set of 
apoptos�s�re��latory prote��s ����� a�t v�a re��lated prote���
prote�� ��tera�t�o�s (14,15). The prote�� fam�ly �s d�v�ded ��to 
t�o �ro�ps: t�e a�t�apoptot�� a�d proapoptot�� fam�ly mem�
�ers, �ased o� ��et�er t�ey �o��tera�t or promote t�e apoptot�� 
pro�ess. B�l�2 a�d B�l�XL are amo�� t�e a�t�apoptot�� prote��s, 
preve�t��� m�to��o�dr�al release of �yto��rome C (16�18), 
��ereas Bax a�d B�l�XS are examples of proapoptot�� prote��s. 
The d�ffere�t mem�ers �ompete ��t� ea�� ot�er �� �o�troll��� 
�yto��rome C release from t�e m�to��o�dr�a (19). Bax ex�sts 
�� a� ��a�t�ve, �ytosol�� form t�at �ets ��serted ��to t�e m�to�
��o�dr�al mem�ra�e o� a proapoptot�� s���al a�d exe��tes �ts 
pro�apoptot�� a�t�v�ty v�a release of �yto��rome C (20,21). There 
may �e a �o��e�t�o� �et�ee� re��lat�o� of express�o� of �erta�� 
B�l�2 fam�ly prote��s a�d apoptos�s �� ad�po�ytes (22,23).
 �ere, �e �ave ��vest��ated t�e poss��le role of apoptos�s �� 
pread�po�ytes a�d l�polys�s �� mat�re ad�po�ytes d�r��� �a��er�
��d��ed �a��ex�a.
Results
Cl����al data from �a��er pat�e�ts ��t� a�d ��t�o�t �a��ex�a are 
prese�ted �� Ta�le 1. The pat�e�ts �� t�e �a��e�t�� �ro�p �ad 
lo�er BM� a�d ser�m al��m�� t�a� t�e �o�trol �ro�p, as ex�
pe�ted from t�e ���l�s�o� �r�ter�a. �� add�t�o�, ser�m �o��e��
trat�o�s of several ad�pok��es �ere meas�red (Ta�le 1). Ser�m 
�o��e�trat�o�s of ��terle�k���6 (�L�6) �ere s����fi�a�tly ����er 
�� t�e �a��e�t�� pat�e�ts �ompared to t�e �o�trols (Ta�le 1). Ad��
po�e�t�� levels �� ser�m te�ded to �e elevated, ��ereas lept�� 
levels te�ded to �e lo�er, ��e� �a��e�t�� pat�e�ts �ere �om�
pared to �o�trol pat�e�ts (Ta�le 1). 
Apoptosis
A pool of pre��rsor pread�po�ytes �a� d�ffere�t�ate a�d reple��
�s� t�e ad�pose t�ss�e ��t� mat�re ad�po�ytes (24). Th�s �ormally 
ma��ta��s t�e l�p�d stor��� �apa��ty of t�e ad�pose t�ss�e d�r��� 
t�e t�r�over of ad�po�ytes. �t �s poss��le t�at �ast��� of ad�pose 




n = 6 P-value
Age (years) 70 (42 - 78) 69 (49 - 80) 0.95
BMI (kg/m2) 19.0 (15.0 - 20.0) 26.5 (22.0 - 32.0) < 0.01
Albumin (mg/mL) 32 (25 - 35) 42 (33 - 49) 0.01
Adiponectin (µg/mL) 23.0 (9.0 - 28.6) 12.6 (4.0 - 25.8) 0.11
Resistin (ng/mL) 24.3 (15.9 - 28.1) 32.4 (13.6 - 66.2) 0.40
Leptin (ng/mL) 2.5 (0.0 - 14.0) 13.0 (2.0 - 22.0) 0.09
IL-6 (pg/mL) 29 (4 - 112) 0 (0 - 50) 0.04
TNF-α (pg/mL) 1.75 (0.80 - 3.10) 1.80 (1.10 - 2.70) 0.85
Table 1. Clinical variables and adipokine serum concentrations in advanced cancer patients with and without cachexia (control)
Values are medians (minimum value - maximum value). P-values indicate differences between the groups according to the Mann-
Whitney U-test. IL-6, interleukin-6; TNF-α, tumor necrosis factor-alpha
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 To test �f ser�m��or�e fa�tors m���t alter t�e de�ree of ap�
optos�s of pread�po�ytes, �e �����ated ��lt�red S�BS pread��
po�ytes ��t� sera from �a��er pat�e�ts ��t� or ��t�o�t �a��ex�
�a. S��seq�e�tly, �e meas�red t�e appeara��e of apoptos�s 
a�d �e�ros�s �s��� ��342 a�d P�, respe�t�vely. For val�dat�o� 
p�rposes S�BS pread�po�ytes �ere �����ated ��t� 100 ��/
mL T�F�a, a�d �e �o�ld d�st�����s� �et�ee� v�a�le �ells (F��. 
1A), apoptot�� �ells (F��. 1B), a�d �e�rot�� �ells (F��. 1C). S�BS 
pread�po�ytes �ere �����ated for 72 � ��t� 10 % ser�m from 
t�e pat�e�ts. Sera from �a��e�t�� pat�e�ts ��d��ed apoptos�s �� 
















































Figure 1. Effect of cachectic patient sera on apoptosis and necrosis in SGBS preadipocytes. Microscopic image of viable (A), 
apoptotic (B) and necrotic (C) SGBS preadipocytes stained with PI and HO342A after incubation with TNFa (8 h; 100 ng/mL). 
SGBS preadipocytes were incubated with sera (72 h; 10 %) from patients with cachexia (n=8) or without cachexia (control; n=6) 
prior to microscopic analysis of apoptosis (D) and necrosis (E). The charts display the proportion of apoptotic or necrotic cells 
relative to viable cells; each point represents mean values of two independent cell experiments with serum from one subject. 
*P ≤ 0.05 using Mann-Whitney U-test
t�e�ts (F��. 1D). The proport�o�s of �e�rot�� �ells �ere s�m�lar 
after �����at�o� ��t� sera from �a��e�t�� a�d �o���a��e�t�� pa�
t�e�ts (F��. 1�). 
 To s��sta�t�ate t�e ��volveme�t of pread�po�yte apoptos�s �� 
�a��ex�a �e meas�red t�e mR�A levels �y RT�PCR of several 
apoptos�s�re��latory prote��s �� t�e B�l�2 fam�ly. Bax a�d B�l�
XS are proapoptot�� prote��s ��ereas B�l�2 a�d B�l�XL are a�t��
apoptot�� prote��s. mR�AB�l�2 �as dete�ted �� J�rkat �ells ��t �ot 
�� t�e S�BS �ells (data �ot s�o��). �� S�BS pread�po�ytes �����
�ated for 72 � ��t� �a��e�t�� sera t�ere �as a te�de��y to�ards 
���reased mR�ABax levels as �ompared ��t� �ells �����ated ��t� 
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�o�trol sera (P = 0.16; F��. 2A). �� �ells �����ated ��t� �a��e�t�� 
sera t�ere �as a �orrelat�o� �et�ee� mR�ABax levels a�d t�e pro�
port�o� of apoptot�� �ells (F��. 2B). After 72 � �����at�o� ��t� 
�a��e�t�� sera mR�A levels of a�t�apoptot�� B�l�XL a�d proapop�
tot�� B�l�XS �ere ���reased a�d de�reased, respe�t�vely, as �om�
pared to �����at�o� ��t� �o�trol sera (F��. 2D,�). 
 Prolo��ed �����at�o� of S�BS pread�po�ytes ��t� �a��e�t�� 
a�d �o�trol sera (7 days), d�d �ot s�o� d�ffere��es �� t�e pro�
port�o� of apoptot�� a�d �e�rot�� �ells (data �ot s�o��). F�r�
t�ermore, t�ere �ere �o d�ffere��e �� Bax, B�l�XL a�d B�l�XS 





















































































Figure 2 Haugen et al.
Figure 2. Effect of cachectic patient sera on expression of genes encoding apoptosis regulatory proteins in SGBS preadipocytes. 
SGBS preadipocytes were incubated in the presence of 10 % sera from cancer patients with cachexia or without cachexia (con-
trol) for 72 h. Then, mRNA levels of apoptosis regulatory proteins were measured by quantitative RT-PCR and normalized to the 
housekeeping gene G3PDH. Relative levels of mRNA encoding the pro-apoptotic protein Bax were calculated (A). Bax mRNA 
levels correlated to the proportion of apoptotic cells (Spearman’s rho = 0.07) after SGBS preadipocytes were incubated with sera 
from patients with cachexia (B). Relative levels of mRNA encoding the anti-apoptotic protein Bcl-XL (C) and the pro-apoptotic 
protein Bcl-XS (D) were also determined. Each point in the diagram represents the mean value of two separate cell experiments 
measured in triplicates. 





















































































Figure 2 Haugen et al.
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Lipolysis
Mat�re, l�p�d�loaded S�BS ad�po�ytes �ere d�ffere�t�ated �� 
v�tro from S�BS pread�po�ytes. Free fatty a��ds �ere released 
��to t�e ��lt�re med��m �po� ��d��t�o� of l�polys�s (F��. 3A). 
D�r��� �a��ex�a ���reased l�polyt�� a�t�v�ty may lead to s�r��k�
��� of ad�po�ytes a�d s��seq�e�tly t�e ad�pose t�ss�e as a ��ole. 
Sera from �a��e�t�� pat�e�ts d�d �ot d�splay ���reased l�polyt�
�� a�t�v�ty ��t, �o�trary to o�r expe�tat�o�s, te�ded to ������t 
l�polys�s �� t�e �ells (P=0.09; F��. 3B). �� add�t�o�, 3T3�L1 �ells 
of m�r��e or���� �ere d�ffere�t�ated ��to ad�po�ytes a�d �sed to 
assay l�polyt�� a�t�v�ty. �� t�e 3T3�L1 ad�po�ytes �a��e�t�� sera 
��d��ed l�polys�s at a ����er rate t�a� sera from �o�trol pat�e�ts 
(F��. 3C). 
Discussion 
��r ma�� fi�d��� �s t�at pread�po�ytes of ��ma� or���� ��l�
t�red �� t�e prese��e of sera from �a��er pat�e�ts ��t� �a��ex�
�a s�o� ���reased apoptos�s ��e� �ompared to pread�po�ytes 
��lt�red ��t� sera from �o�trol pat�e�ts. Pread�po�ytes are 













































































Figure 3 Haugen et al.
Figure 3. Effect of cachectic patient sera on lipolysis in cultured adipocytes. SGBS preadipocytes were differentiated into adi-
pocytes prior to measurements of lipolysis, estimated as the release of fatty acids into the culture media. Lipolysis was induced 
in SGBS adipocytes after treatment with various doses of isoprenaline (3-100,000 nM; 4 h) (A). Mature SGBS adipocytes were 
exposed to sera (3 %) from patients with cachexia and without cachexia (control) for 4 h and the lipolytic activity was measured 
(B). The 3T3-L1 cell line of murine origin was differentiated into adipocytes prior to incubation with patient sera (3 %; 4 h) and 
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�ytes. De�reased ��m�ers of ad�po�ytes may a��o��t for t�e 
loss of ad�pose t�ss�e mass d�r��� �a��ex�a. Moreover, a red���
t�o� �� ad�po�yte ��m�er �s �ypot�es�zed to o���r v�a pread��
po�yte a�d ad�po�yte apoptos�s, a�d poss��ly ad�po�yte ded�f�
fere�t�at�o� (25). Apoptos�s �� ad�po�ytes �as �ee� o�served 
d�r��� �a��er �a��ex�a �� ra���ts a�d pat�e�ts (26, 27). ��r 
fi�d���s s�o� t�at also apoptos�s of pread�po�ytes may play a 
role d�r��� �a��ex�a. 
 Capa��t�es for apoptos�s of pread�po�ytes may vary amo�� 
d�ffere�t fat depots (28), a�d S�BS pread�po�ytes may �ot re�
fle�t t�e �a��e�t�� pro�ess �� all of t�em. After treatme�t ��t� 
or ��t�o�t �a��e�t�� sera, o�ly a small proport�o� of t�e S�BS 
pread�po�ytes sta��ed ��t� ��342 d�splayed altered morp�ol�
o�y of t�e ���lear ��romat�� �o�s�ste�t ��t� apoptos�s. S��� 
alterat�o�s are asso��ated ��t� late sta�es of t�e apoptot�� pro��
ess a�d �t �s poss��le t�at t�e met�odolo�y �sed �ere leads to a� 
��derest�mat�o� of t�e ��m�er of apoptot�� �ells. 
 W�ereas apoptos�s �as e��a��ed �� S�BS pread�po�ytes ���
���ated ��t� sera from �a��e�t�� �a��er pat�e�ts, �e�rot�� �ell 
deat� �as ����a��ed. Deta��me�t of �e�rot�� �ells from t�e 
s�rfa�e of t�e ��lt�re d�s� may expla�� t��s ���o�s�ste��y. �t �s 
also poss��le t�at t�e ��d��t�o� of apoptos�s �s o�ly start��� after 
3 days (72 �) of �����at�o�, a�d t�at a ��m�lat�ve effe�t o� t�e 
��m�er of �e�rot�� �ells o���rs at a later t�me�po��t. Alt�o��� 
sera from t�e �a��e�t�� �ro�p te�ded to ���rease t�e ��m�er of 
�e�rot�� pread�po�ytes after 7 days of �����at�o�, t��s �as st�ll 
�ot stat�st��al s����fi�a�t (data �ot s�o��). L�m�tat�o�s �� o�r 
a��l�ty to �o��l�de may �e d�e to t�e relat�vely small ��m�er of 
pat�e�ts �� o�r st�dy a�d var�at�o� d�e to �etero�e�o�s types of 
�a��er. 
 The effe�t of sera from �a��e�t�� �a��er pat�e�ts, �.e. �ell deat� 
or �ell s�rv�val, may depe�d o� t�e �ala��e of pro� a�d a�t��ap�
optot�� med�ators. Moreover, t�e mR�A levels of a�t�apoptot�� 
B�l�XL a�d proapoptot�� B�l�XS �ere ���reased a�d de�reased, 
respe�t�vely, as �ompared to �����at�o� ��t� �o�trol sera. Th�s 
fi�d��� �as s�rpr�s���, ��t may represe�t a �ompe�satory re�
spo�se. There �as a te�de��y to�ards ���reased mR�A levels 
of proapoptot�� Bax after �����at�o� ��t� �a��e�t�� sera. ��r 
fi�d���s s���est t�at Bax �s a �etter meas�re t�a� B�l�XL for 
apoptos�s �� o�r exper�me�tal set��p.
There are several p�tat�ve med�ators of apoptos�s ����� may 
�e prese�t �� �a��e�t�� sera. Pro��flammatory �ytok��es s��� 
as T�F�α a�d �L�6 �ave �ee� �mpl��ated �� ad�pose atrop�y �� 
�a��ex�a (11). W�ereas T�F�α ��d��es apoptos�s (29), �L�6 �as 
�ee� s�o�� to represe�t a� a�t��apoptot�� s���al (30,31). �� a��
�orda��e ��t� prev�o�s st�d�es (32), t�e �a��e�t�� sera �sed �� 
o�r prese�t st�dy �o�ta��ed ����er levels of �L�6 t�a� t�e �o��
�a��e�t��, ��ereas T�F�α levels �ere s�m�lar. The ���reased �L�6 
levels m���t represe�t a �ompe�satory respo�se to ���reased 
levels of some ���de�t�fied proapoptot�� fa�tor.
 Also ad�pok��es m���t affe�t apoptos�s (33). Ad�po�e�t�� a�d 
lept�� �o��e�trat�o�s te�ded to �e altered �� ser�m from �a�
��e�t�� pat�e�ts as �ompared to �o���a��e�t�� pat�e�ts. Be�a�se 
t�e levels of �ot� t�ese ad�pok��es �� ser�m are ��fl�e��ed �y 
t�e mass of ad�pose t�ss�e, �e �a��ot �o��l�de from o�r st�dy 
t�at �a��ex�a per se affe�ts ad�pok��e levels. F�rt�er st�d�es of 
ad�pok��e �o��e�trat�o�s �� BM��mat��ed �a��er pat�e�ts are 
�arra�ted to determ��e �f ad�pok��es may play a role �� �a��er 
�a��ex�a.
Conclusion 
Fa�tors ��r��lat��� �� t�e �lood of �a��er pat�e�ts ��t� �a��ex�a 
�a� ���rease apoptos�s of pread�po�ytes in vitro.
Methods 
Origin of serum samples. Ser�m �as �olle�ted from pat�e�ts 
for �se �� ��olo���al assays mo��tor��� apoptos�s a�d l�polys�s 
�� ad�po�ytes. The pat�e�ts �ere re�r��ted at Ullevål U��vers�ty 
�osp�tal, �slo. ���l�s�o� �r�ter�a �ere: ��stolo���ally d�a��osed 
�a��er �� l���, k�d�ey, stoma��, pa��reas, �olo� or re�t�m. All 
pat�e�ts ���l�ded �ad metastat�� d�sease determ��ed �y �l����al 
a�d rad�olo���al fi�d���s. Ser�m samples �ere �olle�ted from a 
�ro�p of �a��er pat�e�ts s�ffer��� from �a��ex�a (� = 8; 4 female, 
4 male) a�d a �ro�p of �a��er pat�e�ts ��t�o�t ev�de�t �a��ex�a 
as �o�trols (� = 6; 1 female, 5 male). The �a��e�t�� �ro�p of pa�
t�e�ts ���l�ded �a��ers or����at��� �� d�ffere�t t�ss�es l�ke pa��
�reas (2), �olo� (1), ve�tr��le (1), k�d�ey (1) a�d l��� (3). The 
�o�trol �ro�p ���l�ded �a��ers or����at��� �� �olo� (4), l��� (1) 
a�d re�t�m (1). The pat�e�ts ���l�ded �� t�e �a��e�t�� �ro�p �ad 
a� adva��ed sta�e of �a��ex�a developme�t. �� t��s st�dy, �a�
��ex�a �as defi�ed �as BM� ≤ 20, a�d loss of �ody �e���t > 5 % 
over t�e past 6 mo�t�s, a�d ser�m al��m�� �o��e�trat�o�s ≤ 37 
m�/mL. Pat�e�ts �� t�e �o�trol �ro�p �ad BM� > 20, �o �e���t 
loss t�e prev�o�s 6 mo�t�s, a�d ser�m al��m�� �o��e�trat�o�s 
> 37 m�/mL. Wr�tte� ��formed �o�se�t �as o�ta��ed from all 
t�e part���pa�ts. The st�dy �as approved �y t�e re��o�al �t���s 
Comm�ttee.
Materials. D�l�e��o’s mod�fied �a�le’s med��m/��tr�e�t M�x 
F12 (DM�M/��tr�e�t M�x F12), RPM��1640, Parker 199, ��o�
t��, DL�pa�tot�e�ate, pe����ll��/streptomy���, L��l�tam��, 
��ma� apo�tra�sferr��, ��ma� ��s�l��, �ort�sol, tr��odot�yro�
���e (T3), dexamet�aso�e, 3��so��tyl�1�met�ylxa�t���e (�B�
M�X), p�osp�ate���ffered sal��e (PBS), prop�d��m �od�de (P�), 
�oe��st 33342 (��342), ��P�S, �ov��e ser�m al��m�� (BSA), 
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d�et�yl pyro�ar�o�ate (D�PC), sod��m dode�yl s�lp�ate (SDS) 
a�d sta�rospor��e �ere �o���t from S��ma C�em��als Co 
(St.Lo��s, M�, USA). Fetal �alf ser�m (FCS) �as from ����o 
BRL (Pa�sley, UK). Ros��l�tazo�e �as a ��ft from �laxoSm�t��
Kl��e (�ssex, UK) ��ereas �a�C�3, �a��, L�Cl a�d ��lo�
roform �ere from Mer�k (Darmstadt, �erma�y). Restr��t�o� 
e�zymes (��oR�), et�yle�e d�am��etetraa�et�� a��d (�DTA), 
Tr�s, et��d��m �rom�de, R�ase ������tor, �sopropyl�b�D�t��o�
�ala�topyra�os�de (�PT�) a�d 5��romo�4���loro�3���dolyl�
b�D��ala�topyra�os�de (X��al) �ere o�ta��ed from Prome�a 
(Mad�so�, W�, USA). A�arose �as �o���t from B�o W��ttaker 
Mole��lar Appl��at�o�s (Ro�kla�d, M�, USA). D�t��ot�re�tol 
(DTT) �as p�r��ased from B�o�Rad La�orator�es (�er��les, 
CA, USA) B������o����� a��d (BCA) Prote�� Assay Rea�e�t �as 
from P�er�e (Ro�kford, �L, USA). T�mor �e�ros�s fa�tor�alp�a 
(T�F�a) �as from R&D Systems ���. (M���eapol�s, M�, USA), 
��ereas �e�oprep™ mR�A Beads �ere o�ta��ed from �e�o�
v�s�o� AS (�slo, �or�ay). �m��s�r�pt™ Reverse Tra�s�r�ptase 
k�t �as �o���t from Q�a�e� �m�� (��lde�, �erma�y), ���le 
T�P�™ Clo���� Rea�t�o� a�d Tra�sformat�o� k�t �as from ���
v�tro�e� Corp. (Carls�ad, CA, USA). J�Tq���k m��� a�d max��
prep k�ts �ere �o���t from �e�omed �m�� (Bad �ey��a�se�, 
�erma�y). L���tCy�ler™ Faststart D�A Master SYBR �ree� �, 
L���tCy�ler™ Faststart D�A Master �y�r�d�zat�o� Pro�es, 
L���tCy�ler™ Color Compe�sat�o� Set, L���tCy�ler™ �ap�llar�es 
a�d L���tCy�ler™ ��str�me�t �ere s�ppl�ed from Ro��e Mole��
�lar B�o��em��als (Ma���e�m, �erma�y). Pr�mers �ere from 
��ro�e�te� (Sera���, Bel���m) a�d la�eled �y�r�d�zat�o� pro�es 
�ere ordered from T�B M�LB��L (Berl��, �erma�y). 
Cells. The S�BS �ells �ere k��dly prov�ded �y Professor Mar�
t�� Wa��ts�� (34). The �ells �ere der�ved from t�e stromal 
�ells fra�t�o� of s����ta�eo�s ad�pose t�ss�e of a� ��fa�t ��t� 
S�mpso���ola���Be�mel sy�drome. D�r��� t�e d�ffere�t�at�o� 
pro�ess S�BS �ells developed a �e�e express�o� patter� s�m��
lar to t�at fo��d �� d�ffere�t�at��� ��ma� pread�po�ytes ��t� a 
��ara�ter�st�� ���rease �� fat �ell�spe��fi� mR�As e��od��� l��
poprote�� l�pase, �ly�ero�3�p�osp�ate de�ydro�e�ase (�PD�), 
�LUT4, lept�� a�d ot�ers. D�ffere�t�ated S�BS �ells ex����ted 
a� ���rease �� �l��ose �ptake �po� ��s�l�� st�m�lat�o� a�d �� 
�ly�erol release �po� �ate��olam��e expos�re. S�BS ad�po�ytes 
�ere morp�olo���ally, ��o��em��ally a�d f���t�o�ally s�m�lar 
to �� v�tro d�ffere�t�ated ad�po�ytes from �ealt�y s���e�ts. The 
S�BS �ells �ere ��lt�red �� DM�M/�am’s F12 med��m s�pple�
me�ted ��t� 10% �eat���a�t�vated FCS, ��ot�� (8 m�/l), DL�
pa�tot�e�ate (8 m�/l), L��l�tam��e (2 mmol/l), a�d streptomy�
���/pe����ll�� (0.1 m�/ml). S�BS pread�po�ytes �ere �ro�� �� 
ser�m��o�ta����� med��m �� 24��ell plates. To ��d��e d�ffere��
t�at�o� to mat�re ad�po�ytes, �o�fl�e�t pread�po�ytes �ere ��l�
t�red �� ser�m�free �asal med��m added 20 �mol/l ��s�l��, 0.01 
m�/ml apo�tra�sferr��, 0.1 mmol/l �ort�sol a�d 200 pmol/l T3 
for 14 days. For t�e first fo�r days of d�ffere�t�at�o� t�e med��m 
�as s�ppleme�ted ��t� 25 �mol/l dexamet�aso�e, 500 mmol/l 
�BM�X a�d 2 mmol/l ros��l�tazo�e. The med��m �as ��a��ed 
t���e a �eek. D�r��� t�e exper�me�ts �ells �ere �����ated ��t� 
DM�M/�am’s F12 med��m s�ppleme�ted ��t� 10% ster�le�
filtered pat�e�t ser�m. The �ell l��e J�rkat �as p�r��ased from 
B�o W��ttaker (Walkers��lle, MD, USA), a�d �as ma��ta��ed �� 
RPM��1640 med��m s�ppleme�ted ��t� 10% �eat���a�t�vated 
FCS, L��l�tam��e (2 mmol/l), a�d streptomy���/pe����ll�� (0.1 
m�/ml).
Cell staining. For m��ros�op�� a�alys�s of �ell v�a��l�ty �� S�BS 
pread�po�ytes, ea�� �ell (0.5 ml) �as first �����ated ��t� 3 µl of 
P� (0.5 m�/ml) �� t�e dark for 30 m��. The� 3 µl of ��342 (1 
m�/ml) �as added a�d �����at�o� �o�t���ed for a�ot�er 30 m�� 
�� t�e dark. D�A sta����� ��t� P� ��d��ates leaky plasma mem�
�ra�es �e�a�se t��s dye �a��ot �ross ��ta�t �ell mem�ra�es. 
��342 �rosses ��ta�t mem�ra�es a�d sta��s D�A �� all �ells. 
P� or ��342 asso��ates ��t� D�A a�d em�t red or �l�e l���t, 
respe�t�vely, ��e� exposed to �ltrav�olet l���t. The �l�e �olor 
�e�omes more ��te�se ��e� ��342 asso��ates ��t� �o�de�sed 
D�A fo��d �� apoptot�� �ells as �ompared to �ormal �ells. At 
least 200 �ells per �ell �ere �o��ted ma��ally �� a ��ko� ��l�pse 
TS 100 fl�ores�e��e m��ros�ope. The �ells �ere p�oto�rap�ed 
��t� a ��ko� D���tal Camera DXM 1200.
mRNA isolation. The med��m �as �e�tly removed from t�e 
�ells a�d 100 ml ��e��old R�A lys�s/���d��� ��ffer (100 mmol/l 
Tr�s p� 8.0, 500 mmol/l L�Cl, 10 mmol/l �DTA, 1% SDS, 5 
mmol/l DTT) �as added to ea�� �ell. The �ells �ere deta��ed 
�y s�rap��� ��t� a p�pette t�p a�d t�e �o�te�ts of tr�pl��ate �ells 
�ere tra�sferred to a� �ppe�dorf t��e a�d �mmed�ately froze� 
�� l�q��d ��tro�e�. Cell lysates �ere stored at –80° C. mR�A �as 
�solated from t�e �ell lysate �s��� �e�oprep™ mR�A Beads a��
�ord��� to t�e ma��fa�t�rer’s proto�ol (�e�ov�s�o� AS, �slo, 
�or�ay). Br�efly, 50 ml ol��o�dT��eads �ere prepared, 300 ml 
froze� �ell lysate �as defrosted a�d so���ated for 1�2 s �efore 
tra�sfer to t�e �eads a�d �����at�o� �� room temperat�re for 
3�5 m��. The �eads �ere �as�ed t���e ��t� 250 ml �as� sol�t�o� 
1 (10 mmol/l Tr�s p� 8.0, 150 mmol/l L�Cl, 1 mmol/l �DTA, 
0.1% SDS), a�d t���e ��t� 250 ml �as� sol�t�o� 2 (10 mmol/l 
Tr�s, p� 8.0, 150 mmol/l L�Cl, 1 mmol/l �DTA). The mR�A �as 
el�ted �� 50 ml D�PC �ater �y �����at�o� at 65° C for at least 2 
m��. The mR�A �as stored at –80° C.
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Quantitative RT-PCR. The RT rea�t�o�s �ere performed �s��� 
�m��s�r�pt™ Reverse Tra�s�r�ptase k�t a��ord��� to t�e ma��
�fa�t�rer’s proto�ol (Q�a�e� �m��, ��lde�, �erma�y). 10 ml 
of t�e mR�A �as �sed �� ea�� rea�t�o�. A L���tCy�ler™ �as 
�sed �� all PCR rea�t�o�s. �t offers k��et�� q�a�t�fi�at�o�, ����� 
�s a fast a�d a���rate �ay for q�a�t�fi�at�o�. The SYBR �ree� 
� dye, ����� �as �sed for t�e �e�es �3PD� a�d Bax, ���ds to 
m��or �rooves �� do��le stra�ded D�A a�d fl�ores�es stro��ly 
��e� �o��d to D�A. �� t�e ���o��d state t�e dye �as rela�
t�vely lo� fl�ores�e��e. The ��te�s�ty of fl�ores�e��e from t�e 
dye ��ll ���rease �� proport�o� to t�e amo��t of D�A �� t�e 
PCR. The mR�AB�l�X �s prese�t as a s�ort a�d a lo�� form. To 
d�st�����s� t�ese mR�As fl�ores�e��e reso�a��e e�er�y tra�s�
fer (FR�T) �y�r�d�zat�o� pro�es �ere �sed. ��e pro�e (B�l�
XS+L) �as la�eled at t�e 3’�e�d ��t� fl�ores�e��, ����� serves as 
a do�or fl�orop�ore. A se�o�d pro�e (B�l�XL) �as la�eled at t�e 
5’�e�d ��t� L���tCy�ler�Red 640, a�d a t��rd pro�e (B�l�XS) �as 
la�eled ��t� L���tCy�ler�Red 705. Bot� L���tCy�ler�Red 640 
a�d �705 serve as a��eptor dyes. W�e� t�e do�or a�d a��ep�
tor pro�es re�o���ze ad�a�e�t ��ter�al seq�e��es �� t�e tar�et 
�e�e, t�e fl�ores�e��e s���al �s �e�erated. The d�ffere�t a��ep�
tor pro�es ��ll fl�ores�e ��t� d�ffere�t �avele��t� d�e to d�ffer�
e�t la�el��� of t�e pro�es, mak��� �t poss��le to q�a�t�fy �ot� 
�D�A prod��ts �� t�e same rea�t�o�. Seq�e��es for pr�mers 
a�d pro�es are des�r��ed (Ta�le 2). The Bax a�d �3PD� pr�m�
ers �ere �sed at a fi�al �o��e�trat�o� of 0.5 mmol/l ea��, B�l�X 
pr�mers 0.75 mmol/l ea��, a�d t�e fi�al �o��e�trat�o� of t�e �y�
�r�d�zat�o� pro�es �as 0.3 mmol/l ea��. The fi�al M�Cl2 �o��e��
trat�o� �as opt�m�zed to 3 mmol/l for all rea�t�o�s. 0.2 ml of t�e 
�D�A template from t�e RT�rea�t�o� �as added for dete�t�o� 
of Bax or �3PD�, ��ereas 0.3 ml �as �sed for B�l�X dete�t�o�. 
The total rea�t�o� vol�me �as ad��sted to 20 ml �s��� ster�le, 
PCR �rade �2�. A �e�at�ve �o�trol �as al�ays ���l�ded ��t� 
t�e samples. PCR pro�rams for �3PD� a�d Bax q�a�t�fi�at�o� 
�ere as follo�s: 95° C, 10 m�� follo�ed �y 45 �y�les of 95° C 10 
s, 60° C 7 s, 72° C 10 s. PCR pro�ram for B�l�X q�a�t�fi�at�o� 
�as: 95° C, 10 m�� follo�ed �y 45 �y�les of 95° C 15 s, 55° C 30 
s, 72° C 10 s. D�e to �ross talk �et�ee� t�e dete�t�o� ��a��els 
of t�e L���tCy�ler™ ��str�me�t ��e� �s��� d�ffere�tly la�elled 
�y�r�d�sat�o� pro�es, a �olor �ompe�sat�o� file �ad to �e �re�
ated �s��� t�e L���tCy�ler™ Color Compe�sat�o� Set. The B�l�
X a�d Bax �e�es �ere �lo�ed to make sta�dard d�l�t�o� ser�es 
for q�a�t�fi�at�o� of t�e respe�t�ve �e�es o� PCR. The T�P�™ 
Clo���� Rea�t�o� a�d Tra�sformat�o� k�t �as �sed a��ord��� 
Target mRNA Sequence
G3PDH Forward primer 5’-TCATCAACGGGAAGCCCATCACCATCTTC-3’
G3PDH Reverse primer 5’-GTCTTCTGGTTGGCAGTAATGGCATGGACT-3’
Bcl-2 Forward primer 5’-TGCACCTGACGCCCTTCAC-3’
Bcl-2 Reverse primer 5’-AGACAGCCAGGAGAAATCAAACAG-3’
Bax Forward primer 5’-ACCAAGAAGCTGAGCGAGTGTC-3’
Bax Reverse primer 5’-ACAAAGATGGTCACGGTCTGCC-3’
Bcl-X Forward primer 5’-CGGGCATTCAGTGACCTGAC-3’
Bcl-X Reverse primer 5’-TCAGGAACCAGCGGTTGAAG-3’
Bcl-XS+L FRET probe 5’-GACAGCATATCAGAGCTTTGAACA-X-3’
Bcl-XL FRET probe 5’-LC Red640-TAGTGAATGAACTCTTCCGGGaAT-p-3’
Bcl-XS FRET probe 5’-LC Red705-ATACTTTTGTGGAACTCTATGGGAACA-p-3’
Fluorescence resonance energy transfer (FRET) hybridisation probes; donor fluorophore fluorescein (X); acceptor dyes Light-
Cycler-Red 640 (LCRed640) and LightCycler-Red 705 (LCRed705); phosphate group (p) to block polymerase extension at free 
3’-end.
Table 2. Sequences of primers and probes used for RT-PCR
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to t�e ma��fa�t�rer’s proto�ol (��v�tro�e� Corp., Carls�ad, CA, 
USA). 4 ml fres�ly made PCR prod��t �as �sed �� ea�� �lo���� 
rea�t�o�, a�d t�e �����at�o� t�me �as set to 30 m��.  ��eS�ot™ 
��em��al tra�sformat�o� �as �t�l�zed, a�d 50 a�d 150 ml from 
ea�� tra�sformat�o� �ere spread o� pre��armed sele�t�ve plates 
(added 40 ml X��al a�d 10 ml �PT�). Plasm�d D�A �solat�o� 
�as performed �s��� t�e J�Tq���k m���� or max�prep k�ts a��
�ord��� to t�e ma��fa�t�rer’s proto�ol (�e�omed �m��, Bad 
�ey��a�se�, �erma�y). The plasm�ds �ere exam��ed �y re�
str��t�o� a�alys�s, �s��� ��oR� as restr��t�o� e�zyme. The D�A 
�o�te�ts of t�e m���� a�d max��preps of t�e respe�t�ve �e�es 
�ere meas�red spe�trop�otometr��ally at 260 �m, a�d sta�dard 
d�l�t�o� ser�es �ere made for PCR. 
Lipolysis measurements. D�r��� 3 days pr�or to t�e exper�me�ts 
S�BS a�d 3T3�L1 ad�po�ytes �ere pre�la�eled ��t� [1�14C]�D�
�l��ose or [1�14C]�A�etate, respe�t�vely. The �ells �ere ��a��ed 
to ser�m free med�a 24 � �efore t�e �����at�o� ��t� pat�e�t sera 
or �sopre�al��e. The �ells �ere �as�ed 3 t�mes ��t� pre�eated 
PBS, a�d t�e� ��ve� �ro�t� med�a ��t�o�t �ormo�es, ��t ��t� 
t�e add�t�o� of fatty a��d free BSA (100 mM) a�d �sopre�al��e or 
3 % ser�m from �a��e�t�� a�d �o�trol pat�e�ts. After 4 �o�rs ���
���at�o� t�e med�a �ere removed a�d t�e rad�oa�t�v�ty released 
�as q�a�t�fied �y �o��t��� a� al�q�ot �� s���t�llat�o� fl��d �s��� 
a s���t�llat�o� �o��ter. S�m�larly, t�e �ells �ere lysed a�d t�e re�
ma����� �ell�asso��ated rad�oa�t�v�ty �as �o��ted. L�polys�s (%) 
�as est�mated �y �al��lat��� (100*released rad�oa�t�v�ty/�ell�
asso��ated rad�oa�t�v�ty).
Statistics. The SPSS soft�are vers�o� 13.0 for W��do�s �as 
�sed for t�e stat�st��al a�alys�s. �o��parametr�� met�ods �ere 
�sed d�e to t�e�r res�sta��e to o�tl�ers a�d ske�ed data d�str����
t�o�. The d�ffere��es �et�ee� �ro�ps �ere tested ��t� t�e �o��
parametr�� Ma���W��t�ey U�test, a�d P ≤ 0.05 �as �o�s�dered 
stat�st��ally s����fi�a�t. Correlat�o�s �� t�e separate �ro�ps �ere 
explored ��t� t�e Spearma� ra�k �orrelat�o� �oeffi��e�t, a�d P 
≤ 0.10 �as �o�s�dered stat�st��ally s����fi�a�t. 
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